Dr. Ada Kung founded Expedient Solutions International early 2015 to provide consulting services for biotechnology and pharmaceutical companies in Taiwan, China, and the US. The emphasis of the services is in the translational medicine to bring drug candidates from discovery to development and clinical trials. Additional services include toxicology, animal efficacy modeling, pharmacokinetics as well as regulatory interaction with local and US FDA and submission documentation preparation.
In 2017, Expedient Solutions International formed an alliance with EPL (Experimental Pathology Laboratories) as well as Aclairo Pharmaceutical Consultants in the USA. EPL is the largest pathological services lab in the world and Aclairo is founded by experienced exFDA reviewers.Together with the alliance Expedient Solutions International provides, ADME and clinical pharmacology and drug development in addition to program/project management and study monitoring as well as a spectrum of regulatory document preparations including: Final Study Reports; Regulatory Applications
Prior to founding Expedient Solutions, Dr. Kung was the CEO of Meridigen Biotech Inc., a Stem Cell companyand Elevant Biopharma, a Protein Therapeutics Research and Development company located in Taipei, Taiwan (2012 to 2015),
From 2010 till 2012, Dr. Kung served as senior vice president for a pharmaceutical company in Taiwan, Taigen following a brief career as a preclinical and regulatory consultant. During her tenure with Taigen, Dr. Kung was responsible for preclinical drug development with company products including anti-infective, chemo-sensitizer, and anti-viral products. Dr Kung was involved in the regulatory submissions to US FDA and China CFDA.
Dr. Ada H. C. Kung is the co-founder of Bridge Pharmaceuticals (Bridge Laboratories and now Pharmaron Corp.) in 2006. She assumed the role of General Manager of the Beijing lab in early 2006. As the GM for the laboratory, she was instrumental in establishing from ground-up one of the first bilingual (English and Chinese) Western standard GLP (Good Laboratory Practices) complied and AAALAC accredited state-of-the-art preclinical testing facilities in Beijing, China.
Dr. Kung was responsible for staff recruitment and training. In this endeavor not only did she recruit and train close to 100 staff and establish technical infrastructure in general toxicology/pathology, pharmacology, animal disease modeling, drug metabolism & pharmacokinetics (DMPK)/bioanalysis, and immunology she also constructed and created the quality assurance (QA) system, IT (Information Technology) and data acquisition systemsin addition to the building of the operational infrastructure including finance, legal and human resources (HR).
Dr. Kung is a career Pharmacologist (animal efficacy modeling and DMPK) and Toxicologist and certified by the American Board of Toxicology. In addition, she has in-depth experience in drug development with small molecules, vaccines, peptides and protein therapeutics. Dr. Kung has extensive expertise in the regulatory and quality systems. She has specialized in Investigational New Drug (IND) and New Drug Application (NDA) submissions to US FDA as well as China CFDA. Dr. Kung was responsible in submitting successfully two of the first IND's to US FDA using data generated from China labs. Dr. Kung has a rare combination of China and US drug development expertise.
Dr. Kung held a variety of top management positions in the US pharmaceutical industry, most recently as Vice President, Product Development and Project Management at Gryphon Therapeutics and as Director, Product Development and Project Management at SRI International.
Dr. Kung has authored a book entitled: Therapeutic Proteins: Pharmacokinetics and Pharmacodynamics as well as author of numerous peer-reviewed papers. She was Invited speaker at many international industry conferences.
Dr. Kung received her Ph.D. from the Ohio State University.
